| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 144.75 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Abundant interferon-γ secretion, potent cytotoxicity, and major histocompatibility complex-independent targeting of a large spectrum of tumors make γδ T cells attractive mediators of cancer immunotherapy. However, a better understanding of the molecular mechanisms involved in tumor cell recognition and γδ T-cell activation is required to improve the limited success of γδ T-cell-mediated treatments. Here, we review key advances in basic knowledge made over the past 3 years and summarize the results of γδ T-cell-based clinical trials concluded to date. We also highlight new research directions on the basis of the modulation of receptors that control the function of γδ T cells.
Description
Keywords
Humans Immunotherapy, Adoptive Lymphocyte activation Neoplasms Receptors, Antigen T-Cell Gamma-delta T-Lymphocyte subsets
Citation
Gomes AQ, Martins DS, Silva-Santos B. Targeting gd T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 2010;70(24):10024-7.